Study of LM-061 in Subjects in Advanced Tumors

Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.

For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks